Autologous bone marrow derived stem cell therapy in patients with type 2 diabetes mellitus – defining adequate administration methods

By | 2018-07-16T14:25:15+00:00 July 16th, 2018|Bone Marrow, Stem Cells|Comments Off on Autologous bone marrow derived stem cell therapy in patients with type 2 diabetes mellitus – defining adequate administration methods

Type 2 diabetes mellitus accounts for 90%-95% of all cases of diabetes mellitus and is caused due to insulin deficiency superimposed on insulin resistance. The former is the major defect resulting in a blunted response of pancreatic beta cells to secrete Insulin in response to increased blood glucose levels.

[pdf-embedder url=”https://www.nsorm.com/wp-content/uploads/2018/07/BM-SC-in-DM-Type-II-IV-vs.-Targeted-July-2017.pdf” title=”BM-SC in DM Type II IV vs. Targeted July 2017″]

About the Author: